Table 1.
Patient characteristics at time of primary diagnosis.
| Total | Total EV Amount * n = 70 (%) | HLA-GEV | ||
|---|---|---|---|---|
| n = 78 (%) | Median [Range] ng/mL | |||
| Age | Median: 67 (42–98) | Median: 67 (42–98) | ||
| FIGO stage | I–II | 7 (10%) | 7 (9%) | 13.3 [2.9–20.5] |
| III | 44 (63%) | 49 (63%) | 13.1 [3.4–60.4] | |
| IV | 19 (27%) | 22 (28%) | 19.5 [4.5–44.9] | |
| Nodal status | N0 | 16 (23%) | 18 (23%) | 12.9 [2.9–36.7] |
| N1 | 32 (46%) | 34 (44%) | 13.6 [3.4–44.9] | |
| unknown | 22 (31%) | 26 (33%) | ||
| Metastases formation | M0 | 51 (73%) | 56 (72%) | 13.1 [2.9–60.4] |
| M1 | 19 (27%) | 22 (28%) | 19.5 [4.5–44.9] | |
| Tumor grading | I-II | 27 (39%) | 30 (38%) | 16.3 [4.5–50.7] |
| III | 43 (61%) | 48 (62%) | 13.2 [2.9–60.4] | |
| Residual tumor | no | 34 (49%) | 37 (47%) | 12.7 [2.9–43.7] |
| yes | 36 (51%) | 41 (53%) | 18.7 [4.5–60.4] | |
| CTC before therapy | negative | 54 (77%) | 61 (78%) | 13.1 [2.9–60.4] |
| positive | 15 (22%) | 16 (21%) | 29.1 [10.4–44.9] | |
| unknown | 1 (1%) | 1 (1%) | ||
| CTC before therapy | MUC negative | 61 (88%) | 70 (90%) | 13.6 [2.9–60.4] |
| MUC positive | 8 (11%) | 7 (9%) | 39.6 [12.2–44.9] | |
| unknown | 1 (1%) | 1 (1%) | ||
| CTC before therapy | EpCAM negative | 64 (92%) | 73 (94%) | 13.3 [2.9–60.4] |
| EpCAM positive | 5 (7%) | 4 (5%) | 32.7 [15.8–44.9] | |
| unknown | 1 (1%) | 1 (1%) | ||
| CTC after therapy | negative | 17 (24%) | 20 (26%) | 12.8 [5.3–47.8] |
| positive | 7 (10%) | 7 (9%) | 12.7 [8.0–44.9] | |
| unknown | 46 (66%) | 51 (65%) | ||
| DTCs before therapy | negative | 40 (57%) | 46 (59%) | 13.6 [2.9–50.7] |
| positive | 28 (40%) | 30 (38%) | 15.0 [6.0–60.4] | |
| unknown | 2 (3%) | 2 (3%) | ||
| Platinum-based chemotherapy | no resistance | 48 (69%) | 51 (66%) | 13.3 [2.9–60.4] |
| resistance | 9 (13%) | 12 (15%) | 15.5 [5.3–44.9] | |
| unknown | 13 (18%) | 15 (19%) | ||
| Recurrence (10y) | no relapse | 23 (33%) | 24 (31%) | 13.2 [3.4–50.7] |
| relapse | 46 (66%) | 53 (68%) | 16.8 [2.9–60.4] | |
| unknown | 1 (1%) | 1 (1%) | ||
| Overall Survival (10y) | alive | 38 (54%) | 41 (53%) | 13.1 [2.9–60.40] |
| dead | 31 (45%) | 36 (46%) | 17.0 [4.5–44.9] | |
| unknown | 1 (1%) | 1 (1%) | ||
CTC—circulating tumor cell; DTCs—disseminated tumor cells; FIGO—Federation of Gynecology and Obstetrics; M0—no metastasis formation; M1—metastasis formation; pN0—no nodal infestation; pN1—nodal infestation; * EV particle could not be obtained for all patients.